立方制药
(003020)
| 流通市值：29.86亿 | | | 总市值：41.35亿 |
| 流通股本：1.37亿 | | | 总股本：1.90亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 357,096,223.21 | 1,553,801,538.88 | 1,080,686,112.23 | 732,436,475.72 |
| 营业收入 | 357,096,223.21 | 1,553,801,538.88 | 1,080,686,112.23 | 732,436,475.72 |
| 二、营业总成本 | 316,973,192.5 | 1,411,384,496.9 | 979,333,366.51 | 660,113,516.51 |
| 营业成本 | 121,913,404.72 | 550,811,176.54 | 382,962,103.11 | 261,868,123.79 |
| 税金及附加 | 5,656,931.59 | 24,861,227.85 | 17,536,828.79 | 10,692,570.65 |
| 销售费用 | 153,417,011.03 | 654,186,454.63 | 458,549,831.31 | 302,485,804.76 |
| 管理费用 | 17,417,750.42 | 70,158,627.39 | 48,881,999.65 | 33,296,782.7 |
| 研发费用 | 18,384,297.18 | 110,780,672.05 | 71,036,638.08 | 51,710,952.03 |
| 财务费用 | 183,797.57 | 586,338.44 | 365,965.57 | 59,282.58 |
| 其中:利息费用 | 399,135.94 | 2,340,416.46 | 1,083,933.49 | 1,401,358.42 |
| 其中:利息收入 | 264,543.17 | 1,888,050.49 | 1,284,481.64 | 1,415,558.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 255,915.54 | 149,013.75 | 87,458.34 | 141,882.36 |
| 加:投资收益 | -906,800.33 | 27,718,188.08 | 27,629,384.28 | 26,123,630.38 |
| 资产处置收益 | - | -1,677.88 | 3,539.82 | 1,769.91 |
| 资产减值损失(新) | -695,051.94 | -10,582,798.69 | -9,599,989.39 | -7,889,083.17 |
| 信用减值损失(新) | -31,145.49 | -887,166.1 | -1,050,933.26 | -1,606,221.27 |
| 其他收益 | 3,052,098.19 | 23,294,581.98 | 18,681,176.65 | 11,929,096.23 |
| 四、营业利润 | 41,798,046.68 | 182,107,183.12 | 137,103,382.16 | 101,024,033.65 |
| 加:营业外收入 | 25,947.73 | 826,790.8 | 216,971.44 | 111,343.53 |
| 减:营业外支出 | 514,152.23 | 1,138,375.23 | 456,769.95 | 255,276.28 |
| 五、利润总额 | 41,309,842.18 | 181,795,598.69 | 136,863,583.65 | 100,880,100.9 |
| 减:所得税费用 | 6,051,633.36 | 18,244,152.15 | 13,751,120.24 | 9,349,840.81 |
| 六、净利润 | 35,258,208.82 | 163,551,446.54 | 123,112,463.41 | 91,530,260.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 35,258,208.82 | 163,551,446.54 | 123,112,463.41 | 91,530,260.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 35,290,847.3 | 165,194,999.37 | 120,941,686.73 | 90,227,143 |
| 少数股东损益 | -32,638.48 | -1,643,552.83 | 2,170,776.68 | 1,303,117.09 |
| 扣除非经常损益后的净利润 | 33,510,313.12 | 126,202,742 | 89,354,640.25 | 66,220,905.9 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.19 | 0.87 | 0.64 | 0.47 |
| (二)稀释每股收益 | 0.19 | 0.87 | 0.64 | 0.47 |
| 九、综合收益总额 | 35,258,208.82 | 163,551,446.54 | 123,112,463.41 | 91,530,260.09 |
| 归属于母公司股东的综合收益总额 | 35,290,847.3 | 165,194,999.37 | 120,941,686.73 | 90,227,143 |
| 归属于少数股东的综合收益总额 | -32,638.48 | -1,643,552.83 | 2,170,776.68 | 1,303,117.09 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-30 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |